Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks

2First Division of Gastroenterology, C Granda Hospital Foundation IRCCS Maggiore Policlinico, University of Milan, alessio.aghemo@policlinico.mi.it, Italy

Hepatitis Monthly:Vol. 12, issue 6; 361-368

Published online:Jun 30, 2012

Article type:Editorial

Received:Jan 01, 2012

Accepted:Jun 01, 2012

How to Cite:DAmbrosio R, Aghemo A. Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks.Hepat Mon.2012;12(6):361-368.https://doi.org/10.5812/hepatmon.6095.

Abstract

Antiviral treatment of chronic hepatitis C virus (HCV) is aimed at the persistent eradication of the virus, the so-called sustained virological response (SVR), with the aim ultimately being to prevent the development of liver-related complications and improve patients’ survival. Patients with HCV-related compensated cirrhosis are the group most likely to benefit from viral clearance, as several retrospective studies have shown liver complications rates to be positively modified by the achievement of a SVR. Whether these benefits rely on viral clearance or on the histological improvements seen following successful interferon (IFn)-based therapies has recently been a matter for debate, as studies have shown cirrhosis to regress in some patients with a SVR. Whatever the mechanisms, cirrhosis has the uncanny ability to be both a dominant indication for therapy, as well as one of the strongest baseline factors associated with reduced efficacy of any IFn-based regimen. This has led to the development of alternative treatment strategies, such as low dose pegylated IFn (PegIFn) monotherapy, that unfortunately has proven to be of limited efficacy. For this reason regimens able to clear the virus without relying on the broad antiviral effect of IFN are eagerly awaited.

Implication for health policy/practice/research/medical education:
Patients with HCV-related compensated cirrhosis are the group most to benefit from antiviral treatment as viral clearance has been shown by several retrospective studies to reduce rates of liver complications.
Please cite this paper as:
D’Ambrosio R, Aghemo A. Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks. Hepat Mon. 2012;12(6): 361-8. DoI: 10.5812/hepatmon. 6095

Keywords

Hepatitis C

Liver Cirrhosis

Virology

Full Text

Full text is available in PDF

Import into EndNote Import into BibTex

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 1
Last Update: 3 weeks ago
Scopus by Title: 1
Last Update: 3 weeks ago
Scopus by Title (Ref): 0
Last Update: 3 weeks ago
CrossRef: 8
Last Update: 2 days ago

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Roberta DAmbrosio:[PubMed][Scholar]
Alessio Aghemo:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks

Abstract

Full Text

Crossmark

Checking

Last Update: 3 weeks ago

Last Update: 3 weeks ago

Last Update: 3 weeks ago

Last Update: 2 days ago